A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

Inclusion Criteria:

1. Informed consent obtained before any study-related activities. Study-relatedactivities are any procedures that are carried out as part of the study, includingactivities to determine suitability for the study.

2. Male or female with diagnosis of congenital haemophilia A of any severity based onmedical records.

3. Age 12 years or above at the time of signing the informed consent.

4. Participants treated with emicizumab once-weekly (QW), once every two weeks (Q2W),or once every four weeks (Q4W) according to the label for at least 8 weeks prior toscreening.

5. Participants choosing to discontinue emicizumab treatment and switch to Mim8 QW,Q2W, or once-monthly (QM) treatment for 26 weeks from start of treatment (Visit 2).

6. Participant and/or caregiver willingness and ability to comply with scheduled visitsand study procedures, including the completion of an electronic diary andpatient-reported outcomes (PRO) questionnaires.

Exclusion Criteria:

1. Participation (i.e., signed informed consent) in any interventional, clinical study,with the exception of emicizumab, with receipt of the last dose within 8 weeks (or 5half-lives of the investigational medicinal product [IMP], whichever is longer)before screening.

2. Any disorder, which in the investigator's opinion might jeopardise the participant'scompliance with the protocol or safety, including ongoing Adverse Events (AEs)associated with emicizumab.

3. Previous participation in this study. Participation is defined as signed informedconsent.

4. Known congenital or acquired coagulation disorders other than haemophilia A.

5. Previous or current thromboembolic disease or events (with the exception of previouscatheter associated thrombosis for which anti-thrombotic treatment is not currentlyongoing) or risk of thromboembolic disease, as evaluated by investigator.

6. Neutralising antibodies towards emicizumab have been detected or, for patientsadherent to emicizumab therapy, are suspected based on clinical and laboratoryassessments.

7. Receipt of FVIII gene therapy at any time.

8. Ongoing or planned immune tolerance induction therapy.

9. Minor or major surgery planned to take place after screening and during the 26-weektreatment period.

10. Known or suspected hypersensitivity to study intervention, related products, anyconstituents of the product or to other monoclonal antibodies.

11. Hepatic dysfunction defined as aspartate aminotransferase (AST) and/or alanineaminotransferase (ALT) greater than (>) 3 times the upper limit combined with totalbilirubin >1.5 times the upper limit measured at screening.

12. Renal impairment defined as estimated glomerular filtration rate (eGFR) lesser thanor equal to (≤) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) forserum creatinine measured at screening.

13. Female who is pregnant, breast-feeding or intends to become pregnant or is ofchildbearing potential and not using highly effective contraceptive method.

14. Mental incapacity, unwillingness to cooperate, or a language barrier precludingadequate understanding and cooperation.

15. Other conditions (e.g. autoimmune disease) or laboratory abnormality that mayincrease risk of bleeding or thrombosis as evaluated by the investigator.